Future trends in the treatment of non-alcoholic steatohepatitis

Pharmacological Research

Volumn 134, Issue , 2018, Pages 289-298

  Fiorucci, Stefano ^a   Biagioli, Michele ^a   Distrutti, Eleonora ^b  

^a UNIVERSITY OF PERUGIA   (Italy)

^b SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

Author keywords

Apoptosis; Fibrosis; FXR; GPBAR1; Inflammation; Intestine; Lipids; Liver; Nuclear receptors; PPARs; Steatohepatitis

Indexed keywords

ACETYL COENZYME A CARBOXYLASE INHIBITOR; ALPHA TOCOPHEROL; ARAMCHOL; BAR 501; BAR 502; CENICRIVIROC; CILOFEXOR; ELAFIBRANOR; EMRICASAN; EXENDIN 4; FIRSOCOSTAT; HORMONE RECEPTOR STIMULATING AGENT; INT 767; LJN 452; LMB 763; NAMODENOSON; NGM 282; OBETICHOLIC ACID; OXYGENASE INHIBITOR; PF 05221304; PIOGLITAZONE; PRADIGASTAT; PREBIOTIC AGENT; PROBIOTIC AGENT; ROSIGLITAZONE; SELONSERTIB; SEMAGLUTIDE; SIMTUZUMAB; SITAGLIPTIN; TROPIFEXOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIINFLAMMATORY ACTIVITY; COMBINATION DRUG THERAPY; DIET THERAPY; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; FECAL MICROBIOTA TRANSPLANTATION; HUMAN; LIVER FIBROSIS; MONOTHERAPY; NONALCOHOLIC FATTY LIVER; NONHUMAN; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; PRURITUS; REVIEW; UNSPECIFIED SIDE EFFECT; ANIMAL; DRUG DEVELOPMENT; DRUG EFFECT; FORECASTING; LIVER; MASS COMMUNICATION; METABOLISM; MOLECULARLY TARGETED THERAPY; SIGNAL TRANSDUCTION; TRENDS;

ANIMALS; DIFFUSION OF INNOVATION; DRUG DISCOVERY; FORECASTING; HUMANS; LIVER; MOLECULAR TARGETED THERAPY; NON-ALCOHOLIC FATTY LIVER DISEASE; SIGNAL TRANSDUCTION;

EID: 85050110689     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2018.07.014     Document Type: Review

References (101)

1. Younossi, Z., et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat. Rev. Gastroenterol. Hepatol. 15 (2018), 11–20.
2. Ibrahim, S.H., et al. Non-alcoholic steatohepatitis pathogenesis: sublethal hepatocyte injury as a driver of liver inflammation. Gut, 2018, 10.1136/gutjnl-2017-315691.
3. Blond, E., et al. EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease in severely obese people: do they lead to over-referral?. Diabetologia 60 (2017), 1218–1222.
4. Chalasani, N., et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American association for the study of liver diseases. Hepatology 67 (2018), 328–357.
5. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO), EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. J. Hepatol. 64 (2016), 1388–1402.
6. Hannah, W.N. Jr., Harrison, S.A., Noninvasive imaging methods to determine severity of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology 64 (2016), 2234–2243.
7. Bedossa, P., Patel, K., Biopsy and noninvasive methods to assess progression of nonalcoholic fatty liver disease. Gastroenterology 150 (2016), 1811–1822.
8. Vilar-Gomez, E., et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology 149 (2015), 367–378.
9. Klebanoff, M.J., et al. Bariatric surgery for nonalcoholic steatohepatitis: a clinical and cost-effectiveness analysis. Hepatology 65 (2017), 1156–1164.
10. Younossi, Z.M., et al. Current and future therapeutic regimens for Non-alcoholic fatty liver disease (NAFLD) and Non-alcoholic steatohepatitis (NASH). Hepatology, 2017, 10.1002/hep.29724.
11. Sanyal, A.J., et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N. Engl. J. Med. 362 (2010), 1675–1685.
12. Lavine, J.E., et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA 305 (2011), 1659–1668.
13. Eslami, L., et al. Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Cochrane Database Syst. Rev., 12, 2013, CD008623, 10.1002/14651858.CD008623.
14. Rakoski, M.O., et al. Meta-analysis: insulin sensitizers for the treatment of non-alcoholic steatohepatitis. Aliment. Pharmacol. Ther. 32 (2010), 1211–1221.
15. Ratziu, V., et al. Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial. Hepatology 51 (2010), 445–453.
16. Liao, H.W., et al. Pioglitazone and cardiovascular outcomes in patients with insulin resistance, pre-diabetes and type 2 diabetes: a systematic review and meta-analysis. BMJ Open, 7, 2017, e013927.
17. Drucker, D.J., Nauck, M.A., The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368 (2006), 1696–1705.
18. Armstrong, M.J., et al. Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis. J. Hepatol. 64 (2016), 399–408.
19. Marra, F., Svegliati-Baroni, G., Lipotoxicity and the gut-liver axis in NASH pathogenesis. J. Hepatol. 68 (2018), 280–295.
20. Suzuki, A., Diehl, A.M., Nonalcoholic Steatohepatitis. Annu. Rev. Med. 68 (2017), 85–98.
21. Ibrahim, S.H., et al. Non-alcoholic steatohepatitis pathogenesis: sublethal hepatocyte injury as a driver of liver inflammation. Gut, 2018, 10.1136/gutjnl-2017-315691.
22. Gao, B., Tsukamoto, H., Inflammation in alcoholic and nonalcoholic fatty liver disease: friend or foe?. Gastroenterology 150 (2016), 1704–1709.
23. Heymann, F., Tacke, F., Immunology in the liver–from homeostasis to disease. Nat. Rev. Gastroenterol. Hepatol. 13 (2016), 88–110.
24. Pejnovic, N., et al. Galectin-3 and IL-33/ST2 axis roles and interplay in diet-induced steatohepatitis. World J. Gastroenterol. 22 (2016), 9706–9717.
25. Berres, M.L., et al. Chemokines as immune mediators of liver diseases related to the metabolic syndrome. Dig. Dis. 28 (2010), 192–196.
26. Brandl, K., Schnabl, B., Intestinal microbiota and nonalcoholic steatohepatitis. Curr. Opin. Gastroenterol. 33 (2017), 128–133.
27. Schuppan, D., et al. Determinants of fibrosis progression and regression in NASH. J. Hepatol. 68 (2018), 238–250.
28. Tsuchida, T., Friedman, S.L., Mechanisms of hepatic stellate cell activation. Nat. Rev. Gastroenterol. Hepatol. 14 (2017), 397–411.
29. Younossi, Z.M., et al. Diagnostic modalities for Non-alcoholic fatty liver disease (NAFLD), Non-alcoholic steatohepatitis (NASH) and associated fibrosis. Hepatology, 2017, 10.1002/hep.29721.
30. Tomlinson, B., et al. Investigational glucagon-like peptide-1 agonists for the treatment of obesity. Expert Opin. Investig. Drugs 25 (2016), 1167–1179.
31. Joy, T.R., et al. Sitagliptin in patients with non-alcoholic steatohepatitis: a randomized, placebo-controlled trial. World J. Gastroenterol. 23 (2017), 141–150.
32. Investigation of Efficacy and Safety of Three Dose Levels of Subcutaneous semaglutide Once Daily Versus Placebo in Subjects With Non-alcoholic Steatohepatitis. ClinicalTrials.gov Identifier: NCT02970942.
33. Exenatide Compared With Insulin Glargine to Change Liver Fat Content in Type 2 Diabetes. ClinicalTrials.gov Identifier: NCT02303730.
34. Staels, B., et al. Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Hepatology 58 (2013), 1941–1952.
35. Ratziu, V., et al. Elafibranor, an agonist of the peroxisome proliferator-activated receptor-alpha and -delta, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening. Gastroenterology. 150 (2016), 1147–1159.
36. Jain, M.R., et al. Dual PPARα/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models. Liver Int, 2017, 10.1111/liv.13634.
37. Kumar, D., et al. Saroglitazar reduces obesity and associated inflammatory consequences in murine adipose tissue. Eur. J. Pharmacol. 822 (2018), 32–42.
38. Wettstein, G., et al. The new-generation pan-peroxisome proliferator-activated receptor agonist IVA337 protects the liver from metabolic disorders and fibrosis. Hepatol. Commun. 1 (2017), 524–537.
39. Fiorucci, S., Distrutti, E., Bile acid-activated receptors, intestinal Microbiota, and the treatment of metabolic disorders. Trends Mol. Med. 21 (2015), 702–714.
40. Fiorucci, S., et al. Farnesoid X receptor: from medicinal chemistry to clinical applications. Future Med. Chem. 4 (2012), 877–891.
41. Neuschwander-Tetri, B.A., et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 385 (2015), 956–965.
42. Ratziu, V., et al. Regenerate: a phase 3, double blind, randomized, placebo-controlled multicenter study of obeticholic acid therapy for nonalcoholic steatohepatitis. J. Hepatol. 64 (2016), S294–S295.
43. FDA adds Boxed Warning to highlight correct dosing of Ocaliva- Feb 1, 2018 https://www.fda.gov/Drugs/DrugSafety/ucm594941.htm.
44. Gege, C., et al. Knocking on FXR's door: the “hammerhead”-structure series of FXR agonists - amphiphilic isoxazoles with potent in vitro and in vivo activities. Curr. Top. Med. Chem. 14 (2014), 2143–2158.
45. de Boer, J.F., et al. Intestinal farnesoid X receptor controls transintestinal cholesterol excretion in mice. Gastroenterology 152 (2017), 1126–1138.
46. Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Participants With Nonalcoholic Steatohepatitis (NASH). ClinicalTrials.gov Identifier: NCT02854605.
47. Study of Safety and Efficacy of Tropifexor (LJN452) in Patients With Non-alcoholic Steatohepatitis (NASH) (FLIGHT-FXR). ClinicalTrials.gov Identifier: NCT02855164.
48. Laffitte, B., et al. Development of LMB763, a novel, orally bioavailable, clinical farnesoid X receptor agonist for the treatment of non-alcoholic steatohepatitis and hepatobiliary disorders. J. Hepatol. 66 (2017), S95–S332.
49. Safety, Tolerability, Pharmacokinetics and Efficacy of LMB763 in patients with NASH. htps://clinicaltrials.gov/ct2/show/NCT02913105.
50. Carino, A., et al. Gpbar1 agonism promotes a Pgc-1α-dependent browning of white adipose tissue and energy expenditure and reverses diet-induced steatohepatitis in mice. Sci. Rep., 7, 2017, 13689.
51. Biagioli, M., et al. The bile acid receptor GPBAR1 regulates the M1/M2 phenotype of intestinal macrophages and activation of GPBAR1 rescues mice from murine colitis. J. Immunol. 199 (2017), 718–733.
52. Carino, A., et al. BAR502, a dual FXR and GPBAR1 agonist, promotes browning of white adipose tissue and reverses liver steatosis and fibrosis. Sci. Rep., 7, 2017, 42801.
53. Zhang, F., et al. Minireview: roles of fibroblast growth factors 19 and 21 in metabolic regulation and chronic diseases. Mol. Endocrinol. 29 (2015), 1400–1413.
54. Inagaki, T., et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab., 2005, 217–225.
55. Harding, T.C., et al. Blockade of nonhormonal fibroblast growth factors by FP-1039 inhibits growth of multiple types of cancer. Sci. Transl. Med., 5, 2013, 178ra39.
56. Harrison, S.A.A.M., et al. NGM282, a novel variant of FGF19, significantly reduces hepatic steatosis and key biomarkers of NASH: results of a phase 2, multicenter, randomized, double-blinded, placebo controlled trial in biopsy-confirmed NASH patients. EASL, 201, 2017.
57. Markan, K.R., et al. Circulating FGF21 is liver derived and enhances glucose uptake during refeeding and overfeeding. Diabetes 63 (2014), 4057–4063.
58. Sanyal, A.C.E., et al. BMS-986036 (Pegylated FGF21) in Patients With non-Alcoholic Steatohepatitis: A Phase 2 Study EASL. 2017.
59. Tiessen, R.G., et al. Safety, tolerability and pharmacodynamics of apical sodium-dependent bile acid transporter inhibition with volixibat in healthy adults and patients with type 2 diabetes mellitus: a randomized placebo-controlled trial. BMC Gastroenterol., 18, 2018, 3.
60. Effect of LIK066 on Body Weight in Patients With Elevated Body Mass Index. ClinicalTrials.gov Identifier: NCT02470403.
61. Takeda, A., et al. The improvement of the hepatic histological findings in a patient with Non-alcoholic steatohepatitis with type 2 diabetes after the administration of the sodium-glucose cotransporter 2 inhibitor ipragliflozin. Intern. Med. 56 (2017), 2739–2744.
62. Honda, Y., et al. The selective SGLT2 inhibitor ipragliflozin has a therapeutic effect on nonalcoholic steatohepatitis in mice. PLoS One, 11, 2016, e0146337.
63. Uto, Y., Recent progress in the discovery and development of stearoyl CoA desaturase inhibitors. Chem. Phys. Lipids 197 (2016), 3–12.
64. Safadi, R., et al. The fatty acid-bile acid conjugate aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease. Clin. Gastroenterol. Hepatol. 12 (2014), 2085–2091.
65. Clinical Trials.gov. A Clinical Trial to Evaluate the Efficacy and Safety of Two Aramchol Doses Versus Placebo in Patients With NASH. https://clinicaltrials.gov/ct2/show/NCT02279524.
66. Kim, C.W., et al. Acetyl CoA carboxylase inhibition reduces hepatic steatosis but elevates plasma triglycerides in mice and humans: a bedside to bench investigation. Cell Metab., 26, 2017, 576.
67. Clinical Trials.gov. Phase 2a, Dose-ranging Study With PF-05221304 in Nonalcoholic Fatty Liver Disease (NAFLD). https://clinicaltrials.gov/ct2/show/NCT03248882.
68. Lawitz, E., et al. Proof of concept study of an apoptosis-signal regulating kinase (ASK1) inhibitor (selonsertib) in combination with an acetyl-CoA carboxylase inhibitor (GS-0976) or a farnesoid X receptor agonist (GS-9674) in NASH. J. Hepathol., 68, 2018, S57, 10.1016/S0168-8278(18)30335-0.
69. Meyers, C.D., et al. Effect of pradigastat, a diacylglycerol acyltransferase 1 inhibitor, on the QTcF interval in humans. Clin. Pharmacol. Drug Dev. 5 (2016), 450–459.
70. Clinical trial. Study to Assess the Efficacy, Safety and Tolerability of LCQ908 in NAFLD Patients ClinicalTrials.gov Identifier: NCT01811472.
71. Fiorucci, S., et al. The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis. Gastroenterology 127 (2004), 1497–1512.
72. Lefebvre, E., et al. Antifibrotic effects of the dual CCR2/CCR5 antagonist Cenicriviroc in animal models of liver and kidney fibrosis. PLoS One, 11, 2016, e0158156.
73. Lefebvre, E., et al. Pharmacokinetics, safety, and CCR2/CCR5 antagonist activity of Cenicriviroc in participants with mild or moderate hepatic impairment. Clin. Transl. Sci. 9 (2016), 139–148.
74. Friedman, S.L., et al. A randomized, placebo controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis. Hepatology 67 (2017), 1754–1767.
75. Sanyal, A., et al. Efficacy and safety of simtuzumab for the treatment of nonalcoholic steatohepatitis with bridging fibrosis or cirrhosis: results of two phase 2b, dose-ranging, randomized, placebocontrolled trials. J. Hepatol., 66, 2017, S54.
76. Younossi, Z.M., et al. Improvement of hepatic fibrosis and patient-reported outcomes in non-alcoholic steatohepatitis treated with selonsertib. Liver Int., 2018, 10.1111/liv.13706.
77. Clinical Trials.gov. Safety and Efficacy of Selonsertib in Adults With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) (STELLAR 4). https://clinicaltrials.gov/ct2/show/NCT03053063.
78. Clinical Trials.gov. Safety and Efficacy of Selonsertib in Adults With Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis (STELLAR 3). https://clinicaltrials.gov/ct2/show/NCT03053050.
79. Clinical Trials.gov. Safety, tolerability, and efficacy of selonsertib, GS-0976, and GS-9674 in adults with nonalcoholic steatohepatitis (NASH). https://clinicaltrials.gov/ct2/show/NCT02781584.
80. Barreyro, F.J., et al. The pan-caspase inhibitor emricasan (IDN-6556) decreases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis. Liver Int. 35 (2015), 953–966.
81. Clinical Trials.gov. Emricasan, a Caspase Inhibitor, for Evaluation in Subjects with Non-Alcoholic Steatohepatitis (NASH) Fibrosis (ENCORENF). https://clinicaltrials.gov/ct2/show/NCT02686762.
82. Clinical trials.gov. A Trial of IDN-6556 in Post Orthotopic Liver Transplant for Chronic HCV (POLT-HCV-SVR). https://clinicaltrials.gov/ct2/show/NCT02138253NCT02138253.
83. N. Chalasani et al. A multicenter, randomized, double-blind, PLB-controlled trial of Galectin-3 inhibitor (GR-MD-02) in patients with NASH cirrhosis and portal hypertension. International Liver Congress. Paris. Apr 14, 2018; 210761. https://ilc-congress.eu/wp-content/uploads/2018/ebooks/scientific_programme/files/basic-html/page160.html.
84. Open-Label Study To Evaluate MN-001 on HDL & Triglyceride in NASH & NAFLD Subjects. ClinicalTrials.gov Identifier: NCT02681055.
85. JKB-121 for the Treatment of Nonalcoholic Steatohepatitis. ClinicalTrials.gov Identifier: NCT02442687.
86. Kolkhof, P., et al. Nonsteroidal antagonists of the mineralocorticoid receptor. Curr. Opin. Nephrol. Hypertens. 24 (2015), 417–424.
87. Efficacy and Safety of MT-3995 in Patients With Non-Alcoholic Steatohepatitis(NASH). ClinicalTrials.gov Identifier: NCT02923154.
88. Clemmons, D.R., et al. Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: a randomized, placebo-controlled trial. PLoS One, 12, 2017, e0179538.
89. González-Sales, M., et al. Population pharmacokinetic analysis of tesamorelin in HIV-infected patients and healthy subjects. Clin. Pharmacokinet. 54 (2015), 285–294.
90. Stanley, T.L., et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA 312 (2014), 380–389.
91. S. Harrison, et al. MGL-3196, a selective thyroid hormone receptor-beta agonist significantly decreases hepatic fat in NASH patients at 12 weeks, the primary endpoint in a 36 week serial liver biopsy study International Liver Meeting, EASL. Paris, April, 11-15 2018. Abstract GS-009.
92. Safar Zadeh, E., et al. The liver diseases of lipodystrophy: the long-term effect of leptin treatment. J. Hepatol. 59 (2013), 131–137.
93. Cohen, S., et al. CF102 an A3 adenosine receptor agonist mediates anti-tumor and anti-inflammatory effects in the liver. J. Cell. Physiol. 226 (2011), 2438–2447.
94. Wieland, A., Frank, D.N., Harnke, B., Bambha, K., Systematic review: microbial dysbiosis and nonalcoholic fatty liver disease. Aliment Pharmacol. Ther. 42 (2015), 1051–1063, 10.1111/apt.13376.
95. Loomba, R., Seguritan, V., Li, W., Long, T., Klitgord, N., Bhatt, A., et al. Gut microbiome-based metagenomic signature for Non-invasive detection of advanced fibrosis in human nonalcoholic fatty liver disease. Cell Metab. 25 (2017), 1054–1062, 10.1016/j.cmet.2017.04.001 e5.
96. García-Lezana, T., Raurell, I., Bravo, M., Torres-Arauz, M., Salcedo, M.T., Santiago, A., et al. Restoration of a healthy intestinal microbiota normalizes portal hypertension in a rat model of nonalcoholic steatohepatitis. Hepatology 67 (2018), 1485–1498, 10.1002/hep.29646.
97. Zhou, D., Pan, Q., Shen, F., Cao, H.X., Ding, W.J., Chen, Y.W., Fan, J.G., Total fecal microbiota transplantation alleviates high-fat diet-induced steatohepatitis in mice via beneficial regulation of gut microbiota. Sci. Rep., 7(1), 2017, 1529, 10.1038/s41598-017-01751-y.
98. Dobbins, R., et al. Solithromycin treatment for 13 weeks improves histological parameters in nonalcoholic steatohepatitis: results of an ongoing pilot study. J. Hepatol. 66 (2017), S543–S750.
99. A Phase ll Study of IMM-124E for Patients With Non-alcoholic Steatohepatitis. ClinicalTrials.gov Identifier: NCT02316717.
100. Weston, C.J., et al. Vascular adhesion protein-1 promotes liver inflammation and drives hepatic fibrosis. J. Clin. Invest. 125 (2015), 501–520.
101. Clinical trials.gov. Different Doses of BI 1467335 Compared to Placebo in Patients With Clinical Evidence of NASH. https://clinicaltrials.gov/ct2/show/NCT03166735.